Launxp Biomedical Co (ROCO:6876) Total Operating Expense: NT$110.93 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
11 GF Score
Price NT$16.00
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co Total Operating Expense?

Launxp Biomedical Co ROCO:6876 -0.62% 11 Total Operating Expense is NT$110.93 Mil as of Dec. 2025. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Launxp Biomedical Co's Total Operating Expense for the six months ended in Dec. 2025 was NT$57.26 Mil. Launxp Biomedical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$110.93 Mil.

Launxp Biomedical Co Total Operating Expense Related Terms

Launxp Biomedical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Launxp Biomedical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co Total Operating Expense Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 34.83 43.62 81.06 84.59 110.93

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 52.15 40.51 44.08 53.67 57.26
ROCO:6876
11GF Score
Launxp Biomedical Co Ltd ROCO:6876
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$110.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of NT$110.93 Mil mean?
Launxp Biomedical Co (ROCO:6876) has a Total Operating Expense of NT$110.93 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Launxp Biomedical Co and its competitors.
Is Launxp Biomedical Co's Total Operating Expense too high?
Launxp Biomedical Co's current Total Operating Expense is NT$110.93 Mil. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's Total Operating Expense compare to VRTX and REGN?
Launxp Biomedical Co's Total Operating Expense of NT$110.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Launxp Biomedical Co and its competitors. Launxp Biomedical Co's current Total Operating Expense is NT$110.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current Total Operating Expense of NT$110.93 Mil. The current Total Operating Expense is NT$110.93 Mil. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current Total Operating Expense is NT$110.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score

Get the complete analysis for ROCO:6876

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.00
Price